Show Summary Details
Page of

AGGF1 and Vascular Disease: Klippel-Trenaunay Syndrome 

AGGF1 and Vascular Disease: Klippel-Trenaunay Syndrome
AGGF1 and Vascular Disease: Klippel-Trenaunay Syndrome

Qiuyun Chen

, Mohammad Reza Amini

, and Qing Kenneth Wang

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2021. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 04 March 2021

Genetic factors contribute to the pathogenesis of Klippel-Trenaunay syndrome (KTS). Studies of a chromosomal mutation of translocation t(5;11)(q13.3;p15.1) associated with KTS led to the molecular cloning of a strong candidate gene, AGGF1 for KTS. A follow-up case-control study revealed significant association between AGGF1 variants and risk of KTS, establishing AGGF1 as the first susceptibility gene for KTS. AGGF1 encodes an angiogenic factor that specifies differentiation of veins by activating the AKT signaling pathway as contrast to VEGFA that specifies arteries by activating the ERK signaling pathway. KTS is genetically heterogeneous, and two other chromosomal abnormalities were reported, a de novo translocation t(8;14)(q22.3;q13) and a de novo extra supernumerary ring chromosome 18. Future studies will identify the genes disrupted by these two anomalies and test the association of the newly-identified genes with KTS. Genetic analysis of KTS may lead to new strategies for diagnosis and treatment of KTS patients and other related vascular diseases. Therapeutic angiogenesis based on gene transfer of AGGF1 has already shown a promise in treating peripheral artery disease in a hindlimb ischemic mouse model.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.